Bicyclo[2.2.1]heptanes and related compounds

A pharmaceutical composition for treating a disorder or condition, the treatment of which can be effected or facilitated by modulating glutamate neurotransmission in a mammal, comprising:

• (a) a compound of the formula I, or a pharmaceutically acceptable salt thereof;
• (b) a serotonin reuptake inhibitor or a serotonin-1A (5HT.sub.1A) receptor ligand, or a pharmaceutically acceptable salt of such inhibitor or ligand;
• and
• (c) a pharmaceutically acceptable carrier;
• wherein the amounts of the compound of formula I and the serotonin reuptake inhibitor or 5HT.sub.1A receptor ligand that are contained in such composition are such that the combination of the two active ingredients is effective in treating such disorder or condition.

A method for treating a disorder or condition, the treatment of which can effected or facilitated by modulating glutamate neurotransmission in a mammal, comprising administering to a mammal requiring such treatment:

• (a) a compound of the formula I, or a pharmaceutically acceptable salt thereof;
• and
• (b) a serotonin reuptake inhibitor or a serotonin-1A (5HT.sub.1A) receptor ligand, or a pharmaceutically acceptable salt of such inhibitor or ligand;
• wherein the amounts of the compound of formula I and the serotonin reuptake inhibitor or 5HT.sub.1A receptor ligand that are employed in such method are such that the combination of the two active ingredients is effective in treating such disorder or condition.

A compound of the formula ##STR6## wherein n is 0-6;

• X is CH.sub.2, CH.sub.2 CH.sub.2 or oxygen;
• Z is CHR or NR.sup.2 ;
• R.sup.1 and R.sup.2 are selected independently from hydrogen, (C.sub.1 -C.sub.6)alkyl, aryl and heteroaryl, wherein said aryl is selected from phenyl and naphthyl and said heteroaryl is selected from 5 and 6 membered aromatic heterocyclic rings that contain from one to four heteroatoms selected, independently, from nitrogen, oxygen and sulfur, and wherein said aryl and heteroaryl moieties can optionally be substituted with one or more substituents that are selected, independently, from halo, --S(C.sub.1 -C.sub.6)alkyl, --S(O)(C.sub.1 -C.sub.6)alkyl, --S(O).sub.2 (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkyl optionally substituted with from one to seven fluorine atoms, (C.sub.1 -C.sub.6)alkoxy optionally substituted with from one to seven fluorine atoms, amino, nitro, cyano, carboxy, --CO.sub.2 (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkylamino, di-[(C.sub.1 -C.sub.6)alkyl]amino phenoxy, anilino and phenylthio;
• and
• R.sup.7 is hydrogen, (C.sub.1 -C.sub.6)alkyl or benzyl
• with the proviso that none of said heteroaryl moieties contains more than one ring oxygen atom or more than one ring sulfur atom.